A new study finds people who take weight-loss drugs also cut back on alcohol consumption. Researchers think the drugs could ...

While B-ALL is the most common childhood cancer and one of the most treatable, some patients face grim outcomes after they ...

Four oral glucagon-like peptide-1 receptor (GLP1R) drugs, currently under Phase III trials, are in the race for approval, ...

The outgoing Biden administration is proposing to have popular weight-loss drugs like Wegovy or Zepbound covered by Medicare ...

Despite higher operating revenues, UPMC reported a $371 million loss, attributing it to increased service demand and rising ...

Several obesity experts said perhaps 20% of patients — as many as 1 in 5 — may not respond well to the medications.

Some of what RFK Jr. says about obesity prevention isn't new. But after having coined the catchy MAHA acronym, it’s likely ...

While Ozempic bodes well for weight loss, some users are concerned the drug's impact also means unwanted changes to their ...

LANGHORNE, PA — Amplity Health shared valuable findings from its latest study on GLP-1 receptor agonist (GLP-1 RA) usage ...

Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

If you're in a relationship that faces struggles with weight and are considering GLP-1 medications like Ozempic, consider ...

For employers wanting to dip a toe into the GLP-1 medications pool, utilization management is recommended to control costs.